Should all cases of high-grade serous ovarian, tubal, and primary peritoneal carcinomas be reclassified as tubo-ovarian serous carcinoma?

International Journal of Gynecological Cancer

Volumn 25, Issue 7, 2015, Pages 1201-1207

  Moss, Esther Louise ^a,b   Evans, Tim ^b   Pearmain, Philippa ^b   Askew, Sarah ^b   Singh, Kavita ^c   Chan, Kiong K ^c   Ganesan, Raji ^c   Hirschowitz, Lynn ^c  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b W Midlands Cancer Intelligence Unit   (United Kingdom)

^c Pan Birmingham Gynaecological Cancer Centre   (United Kingdom)

Author keywords

High grade serous carcinoma; Ovarian carcinoma; Primary peritoneal carcinoma; Survival; Tubal carcinoma

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CARCINOSARCOMA; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PRIORITY JOURNAL; UTERINE TUBE CARCINOMA; ADENOCARCINOMA; CANCER GRADING; CLASSIFICATION; COLLOID CARCINOMA; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; FOLLOW UP; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; UTERINE TUBE TUMOR; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 84940923342     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000477     Document Type: Article

References (34)

1. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164:1511-1518.
2. Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719-725.
3. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456.
4. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001;25:1283-1289.
5. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11:6116-6126.
6. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
7. Salvador S, Rempel A, Soslow RA, et al. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Gynecol Oncol. 2008;110:408-417.
8. Gilks CB, Irving J, Kobel M, et al. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal ori gin of high-grade serous carcinomas. Am J Surg Pathol. 2015;39:357-364.
9. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1-5.
10. Singh N, Gilks CB, Wilkinson N, et al. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology. 2014;65:149-154.
11. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407-1416.
12. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancerVshifting the paradigm. Hum Pathol. 2011;42:918-931.
13. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepith elial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-4165.
14. Horn LC, Kafkova S, Leonhardt K, et al. Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas. Int J Gynecol Pathol. 2013;32:339-344.
15. Worley MJ, Welch WR, Berkowitz RS, et al. Endometriosis-Associated ovarian cancer: a review of pathogenesis. Int J Mol Sci. 2013;14:5367-5379.
16. Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian low-And high-grade serous neoplasms. Histopathology. 2013;62:44-58.
17. Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol. 1993;51:171-174.
18. Eisenhauer EL, Sonoda Y, Levine DA, et al. Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma. A m J Obstet Gynecol. 2008;198:213e1-213e7.
19. Jaaback KS, Ludeman L, Clayton NL, et al. Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. Int J Gynecol Cancer. 2006;16:123-128.
20. Dubernard G, Morice P, Rey A, et al. Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J Surg Oncol. 2004;30:976-981.
21. Bakkar R, Gershenson D, Fox P, et al. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses. Int J Gynecol Pathol. 2014;33:302-308.
22. Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol. 1996;60:393-3 96.
23. Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584-2589.
24. Makar AP, Baekelandt M, Trope CG, et al. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian canc er. Gynecol Oncol. 1995;56:175-180.
25. Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994;10:31-46.
26. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138-1150.
27. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044.
28. Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331-334.
29. Bergamini A, Leone Roberti Maggiore U, Ferrero S, et al. Investigational therapies currently in phase II clinical trials for the trea tment of pelvic serous carcinomas. Expert Opin Investig Drugs. 2015; (24):345-62:1-18.
30. Chan A, Gilks B, Kwon J, et al. New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening. Obstet Gynecol. 2012;120: 935-940.
31. McAlpine JN, Hanley GE, Woo MM, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiat ive for ovarian cancer prevention. Am J Obstet Gynecol. 2014;210:471e1Ye11.
32. Gynaecologists RANZCOG. Managing the adnexae at the time of hysterectomy for benign gynaecological disease College Statement C-Gyn In: Melbourne, Australia:RANZCOG; 2012.
33. Oncology SoG. SGO Clinical Practice Statement: Salpingectomy for Ovarian Cancer Prevention. Chicago, IL: SGO; 2013.
34. The Distal Fallopian Tube as the Origin of Non-Uterine Pelvic High-Grade Serous Carcinomas. Royal College of Obstetricians and Gynaecologists, London, UK. 2014.